Floatz logo

CABAZITAXEL

Recurrent Brain Metastases

AIO-Studien-gGmbHSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Brain Metastases cohort.

Asset / SponsorPhaseRating
Epirubicin
Massachusetts General Hospital
Phase 2CCC
Palbociclib
Massachusetts General Hospital
Phase 2CCC
Pembrolizumab
Massachusetts General Hospital
Phase 2CCC
Cyclophosphamide
Massachusetts General Hospital
Phase 2CCC
Meclofenamic Acid
Memorial Sloan Kettering Cancer Center
N/AD

Same molecule, other indications

CABAZITAXEL is also rated in:

metastatic prostate carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
66 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →